{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:51:10Z","timestamp":1777092670942,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":292,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.rmcr.2021.101529","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T02:33:04Z","timestamp":1634869984000},"page":"101529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Mariko","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuhiko","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-3427","authenticated-orcid":false,"given":"Kanoko","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-1356","authenticated-orcid":false,"given":"Miho","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Kin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Funada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2021.101529_bib1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2021.101529_bib2","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2021.101529_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmcr.2021.101529_bib4","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2021.101529_bib5","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/0284186X.2018.1433877","article-title":"Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer","volume":"57","author":"Jensen","year":"2018","journal-title":"Acta Oncol."},{"key":"10.1016\/j.rmcr.2021.101529_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review","volume":"9","author":"van Eeden","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.rmcr.2021.101529_bib7","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jtho.2016.10.008","article-title":"Anti-PD-1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Reungwetwattana","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2021.101529_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.rmcr.2021.101529_bib9","article-title":"Development of Mycobacterium avium complex lung disease in patients with lung cancer on immune checkpoint inhibitors, open","volume":"7","author":"Fujita","year":"2020","journal-title":"Forum. Infect. Dis."},{"key":"10.1016\/j.rmcr.2021.101529_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000866","article-title":"Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors","volume":"5","author":"Anand","year":"2020","journal-title":"ESMO. Open."},{"key":"10.1016\/j.rmcr.2021.101529_bib11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan, emerg","volume":"22","author":"Namkoong","year":"2016","journal-title":"Infect. Dis"},{"key":"10.1016\/j.rmcr.2021.101529_bib12","doi-asserted-by":"crossref","first-page":"106164","DOI":"10.1016\/j.rmed.2020.106164","article-title":"Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation","volume":"173","author":"Schildkraut","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmcr.2021.101529_bib13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2021.101529_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221300712100191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221300712100191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:04:34Z","timestamp":1761959074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221300712100191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":14,"alternative-id":["S221300712100191X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2021.101529","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2021.101529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101529"}}